{
    "id": "3531e516-f3e9-02e7-e063-6294a90a7846",
    "indications": {
        "text": "pediatric information patients 7 17 years age approved astrazeneca \u2019 crestor ( rosuvastatin calcium ) tablets . however , due astrazeneca \u2019 marketing exclusivity rights , product labeled pediatric information .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 rosuvastatin calcium tablets taken without food , time day . ( 2.1 ) \u2022 dose range : 5-40 mg daily . 40 mg dose patients reaching ldl-c goal 20 mg. ( 2.1 ) \u2022 adult hofh : starting dose 20 mg/day ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rosuvastatin calcium tablets supplied : 10 mg : \ufeffyellow , round , biconvex , coated tablets . debossed \u2018 cy \u2019 one side , \u2018 10 \u2019 side . ndc 71335-9640-1 : 30 tablets bottle ndc 71335-9640-2 : 90 tablets bottle ndc 71335-9640-3 : 60 tablets bottle ndc 71335-9640-4 : 120 tablets bottle ndc 71335-9640-5 : 180 tablets bottle ndc 71335-9640-6 : 100 tablets bottle storage store controlled room temperature , 20\u00bac 25\u00bac ( 68\u00baf 77\u00baf ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "rosuvastatin contraindicated following conditions : \u2022 patients known hypersensitivity component product . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin [ ( 6.1 ) ] . \u2022 patients active liver disease , may include unexplained persistent elevations hepatic transaminase levels [ ( 5.3 ) ] . \u2022 pregnancy [ ( 8.1 , 8.3 ) ] . \u2022 lactation . limited data indicate rosuvastatin present human milk . statins potential serious nursing infants , women require rosuvastatin treatment breastfeed infants [ ( 8.2 ) ] .",
    "ingredients": [
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ],
    "organization": "Bryant Ranch Prepack",
    "name": "Rosuvastatin Calcium",
    "effectiveTime": "20250515",
    "indications_original": "Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca\u2019s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca\u2019s marketing exclusivity rights, this drug product is not labeled with that pediatric information.",
    "contraindications_original": "\u2022 Rosuvastatin calcium tablets can be taken with or without food, at any time of day. ( 2.1 ) \u2022 Dose range: 5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg. ( 2.1 ) \u2022 Adult HoFH: Starting dose 20 mg/day ( 2.1 )",
    "warningsAndPrecautions_original": "Rosuvastatin calcium tablets are supplied as:\n                  \n                  \n                     10 mg: \ufeffYellow, round, biconvex, coated tablets. Debossed as \u2018CY\u2019 on one side, and \u201810\u2019 on other side.\n \n                  \n                     NDC 71335-9640-1: 30 Tablets in a BOTTLE\n                     NDC 71335-9640-2: 90 Tablets in a BOTTLE\n                     NDC 71335-9640-3: 60 Tablets in a BOTTLE\n                     NDC 71335-9640-4: 120 Tablets in a BOTTLE\n                     NDC 71335-9640-5: 180 Tablets in a BOTTLE\n                     NDC 71335-9640-6: 100 Tablets in a BOTTLE\n                  \n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20\u00baC to 25\u00baC (68\u00baF to 77\u00baF); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP\n                  Controlled Room Temperature]. Protect from moisture.\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "Rosuvastatin is contraindicated in the following conditions:\n                  \u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin\n \n  [see\n  \n   Adverse Reactions (6.1)]\n \n  .\n\n \n                  \u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels\n \n  [see\n  \n   Warnings and Precautions (5.3)]\n \n  .\n\n \n                  \u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Pregnancy\n \n  [see\n  \n   Use in Specific Populations\u00a0(\n  \n   8.1,\n  \n   8.3)]\n \n  .\n\n \n                  \u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Lactation. Limited data indicate that rosuvastatin is present in human milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require rosuvastatin treatment should not breastfeed their infants\n \n  [see\n  \n   Use in Specific Populations (8.2)]\n \n  .",
    "drug": [
        {
            "name": "Rosuvastatin Calcium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ]
}